Application of a FLAP-consensus docking mixed strategy for the identification of new fatty acid amide hydrolase inhibitors - PubMed (original) (raw)

. 2015 Mar 23;55(3):667-75.

doi: 10.1021/ci5006806. Epub 2015 Mar 12.

Affiliations

• PMID: 25746133
• DOI: 10.1021/ci5006806

Application of a FLAP-consensus docking mixed strategy for the identification of new fatty acid amide hydrolase inhibitors

Giulio Poli et al. J Chem Inf Model. 2015.

Abstract

Fatty acid amide hydrolase (FAAH) is the principal responsible for the termination of anandamide signaling, a major actor of the endocannabinoid system. The indirect stimulation of endocannabinoid responses achieved through FAAH inhibition can represent a valid pharmacological strategy for the treatment of neurodegenerative and neuroinflammatory diseases such as multiple sclerosis, Alzheimer's, Huntington's, and Parkinson's diseases, as well as rheumatoid arthritis, gastrointestinal inflammatory states, anxiety, and other pathologies. With the aim of identifying new noncovalent FAAH inhibitors and also experimentally validating the reliability of the recently reported consensus docking approach, we filtered a commercial database of about 1 million compounds by using a mixed FLAP (fingerprints for ligands and proteins) consensus docking approach. Enzymatic assays showed FAAH inhibitory activity and selectivity versus MAGL for 8 out of the 10 top ranked compounds, with IC50 values in the low micromolar range for the two most active compounds. These results demonstrate the reliability of the virtual screening strategy and constitute an experimental validation of the consensus docking approach. Moreover, the two most active compounds described could represent promising leads for the development of high potent noncovalent FAAH inhibitors.

PubMed Disclaimer

Similar articles

• Computational insights into function and inhibition of fatty acid amide hydrolase.
  Palermo G, Rothlisberger U, Cavalli A, De Vivo M. Palermo G, et al. Eur J Med Chem. 2015 Feb 16;91:15-26. doi: 10.1016/j.ejmech.2014.09.037. Epub 2014 Sep 16. Eur J Med Chem. 2015. PMID: 25240419 Review.
• Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
  Aghazadeh Tabrizi M, Baraldi PG, Ruggiero E, Saponaro G, Baraldi S, Romagnoli R, Martinelli A, Tuccinardi T. Aghazadeh Tabrizi M, et al. Eur J Med Chem. 2015 Jun 5;97:289-305. doi: 10.1016/j.ejmech.2015.04.064. Epub 2015 May 5. Eur J Med Chem. 2015. PMID: 26002335
• 1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling.
  Käsnänen H, Minkkilä A, Taupila S, Patel JZ, Parkkari T, Lahtela-Kakkonen M, Saario SM, Nevalainen T, Poso A. Käsnänen H, et al. Eur J Pharm Sci. 2013 Jun 14;49(3):423-33. doi: 10.1016/j.ejps.2013.03.015. Epub 2013 Apr 2. Eur J Pharm Sci. 2013. PMID: 23557840
• Scaffold hopping-guided design of some isatin based rigid analogs as fatty acid amide hydrolase inhibitors: Synthesis and evaluation.
  Jaiswal S, Tripathi RKP, Ayyannan SR. Jaiswal S, et al. Biomed Pharmacother. 2018 Nov;107:1611-1623. doi: 10.1016/j.biopha.2018.08.125. Epub 2018 Sep 7. Biomed Pharmacother. 2018. PMID: 30257379
• Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure.
  Lodola A, Rivara S, Mor M. Lodola A, et al. Adv Protein Chem Struct Biol. 2011;85:1-26. doi: 10.1016/B978-0-12-386485-7.00001-6. Adv Protein Chem Struct Biol. 2011. PMID: 21920320 Review.

Cited by

• Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
  Poli G, Jha V, Martinelli A, Supuran CT, Tuccinardi T. Poli G, et al. Int J Mol Sci. 2018 Jun 23;19(7):1851. doi: 10.3390/ijms19071851. Int J Mol Sci. 2018. PMID: 29937490 Free PMC article.
• Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.
  Poli G, Lapillo M, Jha V, Mouawad N, Caligiuri I, Macchia M, Minutolo F, Rizzolio F, Tuccinardi T, Granchi C. Poli G, et al. J Enzyme Inhib Med Chem. 2019 Dec;34(1):589-596. doi: 10.1080/14756366.2019.1571271. J Enzyme Inhib Med Chem. 2019. PMID: 30696302 Free PMC article.
• SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia.
  Åbacka H, Masoni S, Poli G, Huang P, Gusso F, Granchi C, Minutolo F, Tuccinardi T, Hagström-Andersson AK, Lindkvist-Petersson K. Åbacka H, et al. Sci Rep. 2024 Apr 20;14(1):9104. doi: 10.1038/s41598-024-58689-1. Sci Rep. 2024. PMID: 38643249 Free PMC article.
• First-of-its-kind STARD3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent.
  Lapillo M, Salis B, Palazzolo S, Poli G, Granchi C, Minutolo F, Rotondo R, Caligiuri I, Canzonieri V, Tuccinardi T, Rizzolio F. Lapillo M, et al. ACS Med Chem Lett. 2019 Feb 20;10(4):475-480. doi: 10.1021/acsmedchemlett.8b00509. eCollection 2019 Apr 11. ACS Med Chem Lett. 2019. PMID: 30996782 Free PMC article.
• Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.
  Poli G, Lapillo M, Granchi C, Caciolla J, Mouawad N, Caligiuri I, Rizzolio F, Langer T, Minutolo F, Tuccinardi T. Poli G, et al. J Enzyme Inhib Med Chem. 2018 Dec;33(1):956-961. doi: 10.1080/14756366.2018.1469017. J Enzyme Inhib Med Chem. 2018. PMID: 29747534 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database